SKIN Stock Overview
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
The Beauty Health Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.06 |
| 52 Week High | US$11.73 |
| 52 Week Low | US$1.35 |
| Beta | 1.02 |
| 1 Month Change | -29.66% |
| 3 Month Change | -0.33% |
| 1 Year Change | -73.48% |
| 3 Year Change | -72.87% |
| 5 Year Change | n/a |
| Change since IPO | -71.77% |
Recent News & Updates
Recent updates
The Beauty Health Company (NASDAQ:SKIN) Stock Rockets 31% But Many Are Still Ignoring The Company
Feb 16
The Beauty Health Company's (NASDAQ:SKIN) Share Price Matching Investor Opinion
Jun 19Is The Beauty Health Company (NASDAQ:SKIN) Trading At A 39% Discount?
May 28At US$13.26, Is The Beauty Health Company (NASDAQ:SKIN) Worth Looking At Closely?
Apr 04Beauty Health's (NASDAQ:SKIN) Earnings Are Of Questionable Quality
Mar 08What Is The Beauty Health Company's (NASDAQ:SKIN) Share Price Doing?
Jan 01An Intrinsic Calculation For The Beauty Health Company (NASDAQ:SKIN) Suggests It's 24% Undervalued
Dec 05The Beauty Health Company: A Compelling Mid To Long-Term Growth Story
Oct 12Beauty-Health Company announces $200M buyback program
Sep 27The Beauty Health Q2 2022 Earnings Preview
Aug 08The Beauty Health Company: Not Looking The Best
Jul 30Beauty Health: Skincare Today And Alpha Tomorrow
May 13Results: The Beauty Health Company Exceeded Expectations And The Consensus Has Updated Its Estimates
May 12Calculating The Intrinsic Value Of The Beauty Health Company (NASDAQ:SKIN)
Apr 22Beauty Health: Growth Over The Next Half-Decade Will Be Material
Nov 29The Beauty Health Company's (NASDAQ:SKIN) Intrinsic Value Is Potentially 59% Above Its Share Price
Oct 11Beauty Health: Q2 Results Support The Bull Thesis
Aug 28A "category creator," Canaccord initiates Beauty Health as a buy; shares up 3%
Jun 15Shareholder Returns
| SKIN | US Personal Products | US Market | |
|---|---|---|---|
| 7D | -10.8% | -0.5% | 1.0% |
| 1Y | -73.5% | -28.8% | 21.9% |
Return vs Industry: SKIN underperformed the US Personal Products industry which returned -26% over the past year.
Return vs Market: SKIN underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| SKIN volatility | |
|---|---|
| SKIN Average Weekly Movement | 11.9% |
| Personal Products Industry Average Movement | 8.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SKIN's share price has been volatile over the past 3 months.
Volatility Over Time: SKIN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 881 | Marla Beck | www.beautyhealth.com |
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company’s flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer’s preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.
The Beauty Health Company Fundamentals Summary
| SKIN fundamental statistics | |
|---|---|
| Market cap | US$377.79m |
| Earnings (TTM) | -US$100.12m |
| Revenue (TTM) | US$397.99m |
0.9x
P/S Ratio-3.8x
P/E RatioIs SKIN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SKIN income statement (TTM) | |
|---|---|
| Revenue | US$397.99m |
| Cost of Revenue | US$242.88m |
| Gross Profit | US$155.11m |
| Other Expenses | US$255.23m |
| Earnings | -US$100.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 38.97% |
| Net Profit Margin | -25.16% |
| Debt/Equity Ratio | 1,243.3% |
How did SKIN perform over the long term?
See historical performance and comparison